The most commonly prescribed GLP-1 agonist is semaglutide, which has gained popularity in recent years after the Food and Drug Administration (FDA) approved it for the treatment of diabetes in 2017 (under the brand name Ozempic), for the treatment of obesity in 2021 (under the brand name Wegovy), and for reducing cardiovascular disease risk in 2024 (Wegovy)
Absolute contraindications include liver disease, kidney disease, G6PD deficiency, pregnancy, and breastfeeding
To achieve sustained success, practices are increasingly integrating emerging weight loss peptides like Tesofensine and 5-Amino-1MQ into their clinical toolkits
In the STEP 1 trial, participants on semaglutide lost an average of 9.7% of their total lean body mass over 68 weeks
Puoi pagare utilizzando la tua carta di credito, anche prepagata (come la Postepay*) attraverso il circuito PayPal anche se non hai un conto PayPal